N-glycans in non-malignant tumor microenvironment cells dampen CAR-T cell function in solid tumors.
Disabling a specific sugar-processing pathway in immune cells restores CAR-T therapy effectiveness against hard-to-treat intestinal and pancreatic cancers.
San Raffaele investigators identified that N-glycans expressed by non-malignant TME cells establish an immunosuppressive niche that limits CAR-T efficacy in CRC and PDAC liver metastases, using transcriptomics, patient samples, and humanized tumor-bearing mouse models with scRNA-seq. Selective MGAT5 disruption in immune/stromal compartments depleted pro-tumor IL1β+ macrophages and restored CAR-T antitumor activity—identifying MGAT5-dependent N-glycan branching as a TME-level actionable target distinct from tumor cell immunoevasion.
What the study was
- Study design
- mechanistic_preclinical
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- J Immunother Cancer
Why it surfaced
Identifies a previously unrecognized TME mechanism limiting solid-tumor CAR-T; MGAT5 is druggable; San Raffaele group has track record of clinical translation; JITC open access; addresses one of the largest unmet needs in cancer immunotherapy.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.